GFRAL and Anorexia: These results show promising potential for a future development of a peptide, to be first tested in vivo and in humans, to ultimately be administrated alone or paired with other therapeutics (for instance, antiemetic agents such as Domperidone, Metoclopramide or Ondansetron), in order to mitigate the effects caused by an excessive amount of GDF15 in pathologies such as CINV or anorexia.[47] However, further investigations are required to improve the pharmacological proprieties of GFRAL antagonists, and to evaluate its potential in the clinical world.